71 related articles for article (PubMed ID: 15920891)
1. A comparison of nonlinear mixed-model analyses for a pediatric pharmacokinetic study.
Hartford A; Migoya E; Maganti L; Porras A; Zhang J
J Biopharm Stat; 2005; 15(3):465-78. PubMed ID: 15920891
[TBL] [Abstract][Full Text] [Related]
2. Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models.
Nguyen TT; Bazzoli C; Mentré F
Stat Med; 2012 May; 31(11-12):1043-58. PubMed ID: 21965170
[TBL] [Abstract][Full Text] [Related]
3. Sample size calculations based on generalized estimating equations for population pharmacokinetic experiments.
Ogungbenro K; Aarons L; Graham G
J Biopharm Stat; 2006; 16(2):135-50. PubMed ID: 16584063
[TBL] [Abstract][Full Text] [Related]
4. Influence of age on the pharmacokinetics of vapiprost, a thromboxane A2 receptor antagonist, and platelet aggregation: comparison of pharmacokinetics by routine approach and population pharmacokinetics.
Ohashi K; Aso R
Int J Clin Pharmacol Res; 2001; 21(2):85-94. PubMed ID: 11824652
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic investigation of actinomycin-D in children and young adults.
Mondick JT; Gibiansky L; Gastonguay MR; Skolnik JM; Cole M; Veal GJ; Boddy AV; Adamson PC; Barrett JS
J Clin Pharmacol; 2008 Jan; 48(1):35-42. PubMed ID: 18094218
[TBL] [Abstract][Full Text] [Related]
6. The bayesian bias correction method of the first-order approximation of nonlinear mixed-effects models for population pharmacokinetics.
Funatogawa T; Funatogawa I
J Biopharm Stat; 2007; 17(3):381-92. PubMed ID: 17479388
[TBL] [Abstract][Full Text] [Related]
7. Use of Bayesian methods for multivariate bioequivalence measures.
Molina de Souza R; Achcar JA; Martinez EZ
J Biopharm Stat; 2009; 19(1):42-66. PubMed ID: 19127466
[TBL] [Abstract][Full Text] [Related]
8. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis.
Anderson BJ; Pons G; Autret-Leca E; Allegaert K; Boccard E
Paediatr Anaesth; 2005 Apr; 15(4):282-92. PubMed ID: 15787918
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic measures, their estimation and selection of sampling times.
Fedorov V; Leonov S
J Biopharm Stat; 2007; 17(5):919-41. PubMed ID: 17885874
[TBL] [Abstract][Full Text] [Related]
10. A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics.
Mentré F; Gomeni R
J Biopharm Stat; 1995 Jul; 5(2):141-58. PubMed ID: 7581424
[TBL] [Abstract][Full Text] [Related]
11. Linezolid pharmacokinetics in pediatric patients: an overview.
Jungbluth GL; Welshman IR; Hopkins NK
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S153-7. PubMed ID: 14520140
[TBL] [Abstract][Full Text] [Related]
12. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel.
Zhang Y; Huo M; Zhou J; Xie S
Comput Methods Programs Biomed; 2010 Sep; 99(3):306-14. PubMed ID: 20176408
[TBL] [Abstract][Full Text] [Related]
13. Confirmatory analysis for phase III population pharmacokinetics.
Hu C; Zhang J; Zhou H
Pharm Stat; 2011; 10(1):14-26. PubMed ID: 20041468
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
[TBL] [Abstract][Full Text] [Related]
15. Sample size calculation for the Power Model for dose proportionality studies.
Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
[TBL] [Abstract][Full Text] [Related]
16. Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model.
Bazzoli C; Retout S; Mentré F
Stat Med; 2009 Jun; 28(14):1940-56. PubMed ID: 19266541
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of ciprofloxacin in pediatric patients.
Rajagopalan P; Gastonguay MR
J Clin Pharmacol; 2003 Jul; 43(7):698-710. PubMed ID: 12856383
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
19. [Comparative pharmacokinetic analysis based on nonlinear mixed effect model].
Li LJ; Li XX; Xu L; Lü YH; Chen JC; Zheng QS
Yao Xue Xue Bao; 2011 Apr; 46(4):447-53. PubMed ID: 21751499
[TBL] [Abstract][Full Text] [Related]
20. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
Jordan P; Brunschwig H; Luedin E
Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
